Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
J Am Coll Cardiol. 2018 Nov 6;72(19):2360-2379. doi: 10.1016/j.jacc.2018.08.2162.
Ejection fraction (EF) reflects both cardiac function and remodeling, and is widely recognized as a valuable diagnostic and prognostic tool. Its use in a variety of settings, ranging from heart failure and myocardial infarction to valvular heart disease, has made it a cornerstone of modern cardiology, pervading guidelines and practice. However, the development of the test was in another era, with younger patients and a lower prevalence of heart failure with preserved EF. The performance expectations of EF in the current era are also demanding-in relation to detection of subclinical LV dysfunction, and especially relating to recognition of changes in LV function on sequential testing-for example in patients taking cardiotoxic drugs. This review discusses whether the impressive evidence base for EF justifies its ongoing use in the context of newer markers of LV function, and the sophisticated questions posed by modern cardiology.
射血分数(EF)反映了心脏功能和重构,被广泛认为是一种有价值的诊断和预后工具。它在心力衰竭、心肌梗死、瓣膜性心脏病等多种情况下的应用,使其成为现代心脏病学的基石,贯穿于指南和实践中。然而,该测试的发展处于另一个时代,年轻患者和射血分数保留心力衰竭的患病率较低。EF 在当前时代的性能预期也很高——与检测亚临床左心室功能障碍有关,特别是与识别连续检测中左心室功能的变化有关,例如在服用心脏毒性药物的患者中。这篇综述讨论了 EF 的令人印象深刻的证据基础是否证明了其在新的左心室功能标志物和现代心脏病学提出的复杂问题的背景下继续使用的合理性。